Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by ANALIAS00on Feb 19, 2018 11:53am

148 Views

Post# 27583124

RE:RE:RE:RE:RE:75%... not too bad.

KMPH	$5.80 +0.15 (+2.62%)	KP201/APAP Acute pain.	PDUFA	02/23/2018 PDUFA date February 23, 2018 - CRL issued June 13, 2016.
SRNE	$8.75 -0.3 (-3.32%)	ZTlido (lidocaine patch 1.8%) Pain associated with post-herpetic neuralgia (PHN)	PDUFA	02/28/2018 PDUFA date for NDA resubmission February 28, 2017.
OTIC	$5.80 +0.1 (+1.75%)	OTIPRIO Acute otitis externa	PDUFA	03/02/2018 Phase 3 trial met primary endpoint - January 5, 2017. PDUFA date for sNDA filing March 2, 2018.
BMY	$68.96 -0.02 (-0.03%)	Opdivo - 4 week applications	PDUFA	03/05/2018 PDUFA date March 5, 2018 for sBLA filings across all approved indications.
PFE	$36.26 +0.55 (+1.54%)	Xeljanz Ulcerative colitis	PDUFA	03/08/2018 sNDA acceptance announced July 13, 2017. 3-month extension announced December 13, 2017.PDUFA date not given. Estimate June 13 using 8 (+3) month timeline. Advisory Committee meeting March 8, 2018.
AMGN	$183.55 -0.05 (-0.03%)	BLINCYTO Minimal residual disease in patients with Acute lymphoblastic leukemia (ALL)	PDUFA	03/29/2018 PDUFA date March 29, 2018. Advisory Committee Meeting March 7, 2018.
THERF	$5.75 +0 (+0%)	Ibalizumab Multi-drug resistant HIV-1	PDUFA	04/03/2018 Original PDUFA date January 3, 2018 extended 3 months to April 3. 2018.